INTERVIEW: AstraZeneca on the Cancer Drugs Fund reforms
February 26, 2016Medical Communications, Research and Development, Sales and Marketing Cancer Drugs Fund
Greg Rossi, head of the Oncology Business Unit, AstraZeneca UK and Ireland, and the company’s market access team, spoke to …
Bayer names Werner Baumann new CEO
February 26, 2016Medical Communications Bayer
Werner Baumann will become the new chief executive of Bayer AG from May 1, the company has announced. The decision …
Obama announces acceleration of Precision Medicines Initiative
February 26, 2016Medical Communications, Research and Development Obama, Precision Medicine, cancer moonshot, genomics
A year after Barack Obama announced the $200 million Precision Medicines Initiative (PMI), the US President yesterday outlined the next …
MHRA approves new indication for MSD’s Ezetrol
February 26, 2016Medical Communications, Research and Development, Sales and Marketing MHRA, MSD, NICE, ezetrol
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication for MSD’s Ezetrol (ezetimibe), making it …
NHS England approves Cancer Drugs Fund proposals
February 26, 2016Medical Communications, Research and Development ABPI, Cancer Drugs Fund, NHS England
NHS England has approved proposed reforms of the Cancer Drugs Fund, following the end of the 12-week consultation period earlier …
EMA recommends AZ/Acerta drug for orphan status in three indications
February 25, 2016Research and Development AstraZeneca, EMA, Orphan Drugs
The European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has recommended AstraZeneca and Acerta’s acalabrutinib (ACP-196) for designation …
The Medicines Patent Pool – five years on
February 25, 2016Research and Development, Sales and Marketing
Introduction The Medicines Patent Pool (MPP) was founded five years ago as a program to improve access to affordable and …
Gilead announces HIV regimen trial results
February 25, 2016Medical Communications, Research and Development, Sales and Marketing Gilead Sciences
Gilead Sciences has reported 48-week Phase III trial results suggesting fixed-dose Emtriva and tenofovir alafenamide (F/TAF) combinations matched its Truvada …
Senate confirms Dr Robert Califf to lead FDA
February 25, 2016Medical Communications Drug pricing, FDA, Robert Califf
The US Senate has confirmed Dr Robert Califf as Commissioner of the Food and Drugs Administration, in an overwhelming 89-4 …
European Commission approves Lilly’s Portrazza for NSCLC
February 24, 2016Research and Development Eli Lilly, Portrazza
The European Commission has approved Eli Lilly’s Portrazza (necitumumab), in combination with gemcitabine and cisplatin chemotherapy, as a first-line treatment …
J&J fined $72 million in talc cancer case
February 24, 2016Research and Development, Sales and Marketing Johnson & Johnson
A Missouri jury has ruled that Johnson & Johnson must pay $72 million to the family of an Alabama woman, …
Janssen says cabotegravir/rilpivirine combo matches three-drug HIV maintenance therapy
February 24, 2016Research and Development Janssen, ViiV
Janssen has announced 32-week data from an ongoing phase IIb study of an HIV regimen comprised of its rilpivirine and …
NeuroVive board selects Erik Kinnman as new CEO
February 23, 2016Mitochondrial medicine specialist NeuroVive Pharmaceutical’s board of directors has selected Erik Kinnman as the company’s new chief executive, from March …
Novo Nordisk says Tresiba reduces hypoglycaemia risk vs Lantus
February 23, 2016Manufacturing and Production, Research and Development Novo Nordisk
Novo Nordisk has announced trial results suggesting that its drug Tresiba (insulin degludec) carries a reduced risk of hypoglycaemia episodes, …
Valeant likely to restate financial results after Philidore review
February 23, 2016Manufacturing and Production, Medical Communications, Sales and Marketing Howard Schiller, Philidore, Valeant
Valeant says it is likely to restate its financial results for the last two years, in the wake of the …
ViiV completes BMS HIV pipeline purchase
February 23, 2016Manufacturing and Production, Medical Communications, Research and Development Bristol-Myers Squibb, GSK, HIV, Pfizer, Shionogi, ViiV
ViiV Healthcare has completed its previously-announced acquisition of Bristol-Myers Squibb’s late-stage HIV R&D assets and its portfolio of preclinical and …
Califf clears key hurdle to FDA top job
February 23, 2016Manufacturing and Production, Medical Communications, Research and Development
Dr Robert Califf, President Obama’s nominee to head up the US Food and Drugs Administration as commissioner, has edged a …
Europe approves Bayer haemophilia drug
February 22, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bayer, haemophilia a
Bayer has received approval from the European Commission for its haemophilia A drug Kovaltry (octocog alfa) in patients of all …
March edition of Pharmafocus live
February 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
The March 2016 edition of Pharmafocus is now live and available to read here.
Amgen and UCB announce positive romosozumab results
February 22, 2016Medical Communications, Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, osteoporosis
Romosozumab development partners Amgen and UCB have announced positive top-line results from a Phase III study of the drug in postmenopausal …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
